

Natco Pharma Limited

Regd. Off.: NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.

Telangana, INDIA. Tel: +91 40 23547532, Fax: +91 40 23548243

CIN: L24230TG1981PLC003201, www.natcopharma.co.in

November 6, 2019

Corporate Relationship Department

M/s. BSE Ltd Dalal Street, Fort Mumbai- 400 001

Scrip Code: 524816

Manager - Listing

M/s. National Stock Exchange of India Ltd "Exchange Plaza", Bandra – Kurla Complex

Bandra (E) Mumbai -400 051

Scrip Code: NATCOPHARM

Dear Sir

Sub: - Earning call for Q2 and half year ended FY20

The Company will host an Earnings Call with Investors / Analysts at **11.00 a.m. IST on November 13, 2019** to disseminate Financial Results of the company for the quarter and half year ended September 30, 2019.

A Copy of the same is enclosed for your ready reference

Thanking you

Yours faithfully

For NATCO Pharma Limited

M Adinarayana

Company Secretary &

Vice President (Legal & Corp Affairs)

NATCO PHARMA



Hosted by Edelweiss Securities

India Equity Research November 06, 2019

We are organising a conference call with the management of NATCO Pharma, to discuss the company's Q2FY20 financial results on Wednesday, November 13, 2019 at 11.00 AM IST.

Mr. Rajeev Nannapaneni (Vice Chairman and Chief Executive Officer) and Mr. Rajesh Chebiyam (Vice President, Acquisitions, Institutional Investor Management and Corporate Communications) will represent NATCO Pharma on the call. The call would run for an hour.

Details of the conference call are as under:

Time : 11.00 AM IST on Wednesday, November 13, 2019

Conference dial-in:			
India	:	Mumbai	
		Primary access number	+91 22 6280 1123
			+91 22 7115 8024
USA	:		1 866 746 2133
UK	:		0 808 101 1573
Singapore Toll Free No.	:		800 101 2045
Hong Kong Toll Free No.	:		800 964 448

Call leader Mr. Deepak Malik

For further information please contact:

Deepak Malik

Edelweiss Securities Ltd. Tel.: +91 22 6620 3147

Fax: +91 22 2286 4310

E-mail: deepak.malik@edelweissfin.com